Fresenius Kabi Faces Decade Wait On US Cinvanti Generic
Novel Formulation For Chemotherapy-Induced Nausea And Vomiting Stands Strong
Fresenius Kabi was unable to persuade a US court that its proposed generic version of Heron Therapeutics’ Cinvanti (aprepitant) injectable emulsion for chemotherapy-induced nausea and vomiting would not infringe a pair of patents stretching into the next decade.
